Several studies have implied the roles of a disintegrin and metalloprotease-17 (ADAM17) in CD16 shedding [65], which is suggested to be a potential hurdle for effective NK cell ADCC therapy, including cancer immunotherapy [66,67]. This evidence concerns the gene ADAM17 and cancer.